| | Supervised exercise | Standard therapy |
|--|---------------------|------------------|
| Antidiabetic drug class ^a , n (%) | (N=110) | (N=114) |
| Any antidiabetic drug therapy | 85 (77.3) | 87 (76.3) |
| Biguanides | 56 (50.9) | 59 (51.8) |
| DPP-4 inhibitors | 56 (50.9) | 56 (49.1) |
| SGLT2 inhibitors | 37 (33.6) | 45 (39.5) |
| α-Glucosidase inhibitors | 6 (5.5) | 7 (6.1) |
| GLP-1 receptor agonists | 5 (4.5) | 5 (4.4) |
| Thiazolidinediones | 4 (3.6) | 6 (5.3) |
| Rapid-acting insulin secretagogues | 0 | 1 (0.9) |
| (glinides) | | |

Abbreviations: DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; SGLT2, sodium/glucose cotransporter 2.

^aPatients who received combinations of drugs from different classes are counted within each class.